Aleeto

Phase 2Small molecule

BBeijing Tiantan Hospital

Aleeto is one of 91 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Ischemic StrokeActive, not recruiting

Multiple System AtrophyActive, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Multiple System AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Aleeto

BBeijing Tiantan Hospital

Phase 2

1 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Multiple System Atrophy

NCT06765733

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial

Recruiting·—·Phase 2·NCT06759753·192 enrolled

Amyotrophic Lateral Sclerosis1 trial

Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis

Unknown status·—·Phase 1·NCT06181526·24 enrolled

Multiple System Atrophy1 trial

The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

Recruiting·—·Phase 1·NCT06765733·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Aleeto. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aleeto compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aleeto. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing Tiantan Hospital

Aleeto

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ischemic stroke1 trial

Amyotrophic Lateral Sclerosis1 trial

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News